Filtering out Stage II patients and subgrouping them by the four CMS subtypes (1–4), we can demonstrate that as in Allen et al.11 that CD8 levels have a significant impact on outcome for patients with Stage III CMS2 tumours in this cohort. Here, CD8A is linked to neoplasm.